PBR Nachrichten

 

The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. It makes the combination the first regimen that pairs a programmed death-1 (PD-1) The post MSD's Keytruda-Padcev combo secures EC approval for MIBC appeared first on Pharmaceutical Business review....

Frazier Life Sciences led the financing round along with new investors EQT Life Sciences, Forbion, Monograph and Wellington Management. LifeArc Ventures, Oxford Science Enterprises and the University of The post RQ Bio secures $115m to develop influenza antibody programme appeared first on Pharmaceutical Business review....

The partnership will combine Combotope's SMART-Phage discovery platform with Boehringer Ingelheim's research and development capabilities, focusing on multiple identified oncology targets. Combotope CEO Ola Blixt said: “At Combotope, The post Boehringer and Combotope partner for cancer antibodies appeared first on Pharmaceutical Business review....

Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco's drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments, The post Haisco and Nuvectis sign licensing deal for two drugs appeared first on Pharmaceutical Business review....

This expands intellectual property protection already in place for Genprex in jurisdictions such as China, Europe, Japan, Russia and the US. Genprex's Reqorsa is currently in development alongside The post Genprex's Reqorsa combo secures Canadian patent for lung cancer appeared first on Pharmaceutical Business review....

The partnership will combine BioArctic's BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully, The post Lilly and BioArctic sign deal to develop neurodegenerative therapy appeared first on Pharmaceutical Business review....

According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close The post Sun Pharma to acquire Innovcare Lifesciences for $28.7m appeared first on Pharmaceutical Business review....

The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks The post Japan approves Sanofi's Sarclisa combo for MM treatment appeared first on Pharmaceutical Business review....

The partnership will bring together Voro Therapeutics' tumour-activated biologics platform with Alloy Therapeutics' cluster of differentiation 3 (CD3) antibodies and multispecific engineering capabilities. This joint effort aims to The post Voro and Alloy partner on tumour-selective TCE therapeutics appeared first on Pharmaceutical Business review....

The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. The proposed acquisition will add several anti-inflammatory candidates The post Biogen to acquire RayThera for up to $1bn appeared first on Pharmaceutical Business review....

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within The post Jazz and AbCellera sign deal for T-cell engagers in solid tumours appeared first on Pharmaceutical Business review....

Executives from both organisations, including LG AI Research head Woohyung Lim and D&D Pharmatech CEO Seulki Lee, attended the event to formalise the partnership. The project focuses on The post LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs appeared first on Pharmaceutical Business review....

The agreement broadens AviadoBio's existing rights, which were previously limited to the development of gene therapies for neurological diseases under a 2020 agreement. The vMiX platform leverages adeno-associated The post AviadoBio broadens vMiX gene silencing licence with King's College London appeared first on Pharmaceutical Business review....

Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026. The company's The post Altaris to acquire Simulations Plus in $375m all-cash deal appeared first on Pharmaceutical Business review....

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy. In the US, the ODD offers incentives such as tax The post Alkermes' alixorexton secures FDA and EC orphan designations appeared first on Pharmaceutical Business review....

This approval is said to be the first in the UK for a needle-free adrenaline treatment for children aged four years and older, weighing between 15kg and less The post ALK's EURneffy secures MHRA approval for anaphylaxis treatment appeared first on Pharmaceutical Business review....

Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the The post Simcere and Stanford partner to develop IPF therapies appeared first on Pharmaceutical Business review....

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. This marks the The post FDA clears MSD's Keytruda combo plus Welireg for ccRCC treatment appeared first on Pharmaceutical Business review....

The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy. The post China's NMPA approves Akeso's gumokimab for plaque psoriasis appeared first on Pharmaceutical Business review....

The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make The post FDA grants priority review for Roche's Tecentriq combo sBLA appeared first on Pharmaceutical Business review....